Basilea Pharmaceutica (OTCMKTS:BPMUF) Sets New 52-Week High – Still a Buy?

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $54.00 and last traded at $54.00, with a volume of 100 shares. The stock had previously closed at $52.83.

Basilea Pharmaceutica Price Performance

The company has a current ratio of 4.10, a quick ratio of 3.27 and a debt-to-equity ratio of 5.70. The stock has a fifty day simple moving average of $52.88 and a two-hundred day simple moving average of $52.58.

About Basilea Pharmaceutica

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Featured Articles

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.